Amgen Inc. (NASDAQ:AMGN)’s thrombocytopenia drug Nplate (romiplostim) showed significant benefits in a Phase III trial for ...

Nplate improved platelet response and reduced therapy modification for patients with chemotherapy-induced thrombocytopaenia.

Amgen’s Nplate (romiplostim) has demonstrated efficacy in treating thrombocytopaenia among gastrointestinal (GI) cancer patients, as Phase III RECITE results are presented at ASCO 2025.

The use of romiplostim as an alternative therapeutic option in the neonatal intensive care unit (NICU) in an effort to avoid multiple platelet transfusions, has proved successful in patients with ...

Thrombopoietin receptor agonists (TPO-RAs), including recombinant human thrombopoietin (rhTPO), romiplostim, and eltrombopag, have emerged as promising therapeutic alternatives for pediatric ITP.